Zacks Analyst Blog Highlights: Motorola, Apple, Abbott Labs, Boston Scientific and Johnson & Johnson.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Motorola Inc. (NYSE NYSE See: New York Stock Exchange : MOT), Apple Inc. (Nasdaq: AAPL AAPL Apple Computer, Inc. (stock symbol) AAPL American Association of Professional Landmen AAPL American Academy of Psychiatry and the Law AAPL Advance Audiovisual Presentation Limited AAPL Advocates for Arkansas Public Libraries ), Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. (NYSE: ABT ABT About ABT Abteilung (German: Department) ABT Abbott Laboratories (stock symbol) ABT American Ballet Theatre ABT Associação Brasileira de Telemarketing ABT Abort ABT Availability Based Tariff ), Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, (NYSE: BSX BSX Bermuda Stock Exchange BSX Bandai Satellaview-X BSX Bicycle Super-X (Cross) ) and Johnson & Johnson (NYSE: JNJ JNJ Johnson and Johnson (stock symbol) JNJ Journal of Nursing Jocularity ). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673. Here are highlights from Thursday's Analyst Blog: Good Price for MOT Motorola Inc. (NYSE: MOT), a leading manufacturer of wireless handsets, network infrastructure and cable products, reported fourth quarter financial results (ended December) that were below our expectations. The company faces tremendous competitive pricing issues in its core mobile devices segment, especially in emerging markets, and, as a result, profit margins decreased significantly. However, the financial fundamentals remain appealing as the company's enterprise network solutions and digital entertainment business segments generate encouraging results. MOT also announced significant opportunities for its WiMax offerings. We believe the current valuation of the company already reflects the negative sentiments related to handset business competition and the recent Apple Inc. (Nasdaq: AAPL) iPhone market entry announcement. We remain positive on MOT's ability to harness higher revenue with new technological offerings and, therefore, maintain our Buy rating. $60 Target on Abbott Labs Abbott Laboratories (NYSE: ABT) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect a sizable pick-up in earnings growth rate over the next few years, driven by strong sales of its lead product Humira, a rapidly growing vascular business, and on several new drug applications recently filed with the Food & Drug Administration [FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ]. Based on our model, the company is expected to deliver double-digit growth from 2007 through 2010. We believe ABT possesses a low risk profile and will continue to trade at an industry premium. Accordingly, we continue to rate the shares a Buy and are increasing our price target to $60. Thanks to the acquisition of Guidant's vascular business in 2006, Abbott is now a major player in the drug-eluting stent In cardiology, a drug-eluting stent is a stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents scar-tissue–like growth that, together with clots (thrombus), could otherwise block the stented (DES) market with XIENCE V. We think XIENCE V offers differentiating characteristics such as superior in-stent late loss and efficacy in diabetic patients to Boston Scientific's (NYSE: BSX) TAXUS and Johnson & Johnson's (NYSE: JNJ) Cypher See cipher. that has allowed market share gains upon the launch overseas. We forecast the XIENCE V U.S. launch in early 2008. Abbott's vascular business, which posted sales of $253 million in 2005, should grow to over $2.7 billion in 2010. For 2007 we forecast $1.92 billion in total vascular sales. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion